ENLIVEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $15.36 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-03
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $0.87, a 83.65% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.04, a 88.79% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $3.66, a 71.82% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $15.36, a 30.06% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $11.81, a 24.39% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $15.62, a 290.50% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.00, a 42.86% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $15.36 10-K · filed 2026-03-03 | ||||
| 2024-12-31 | $11.81 10-K · filed 2026-03-03 | ||||
| 2023-12-31 | $15.62 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $4.00 10-K · filed 2024-03-14 | $1.02 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-10-25 | $1.02 10-Q · filed 2022-10-25 | |||
| 2022-06-30 | $0.87 10-Q · filed 2022-08-03 | $1.02 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $1.04 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | $7.00 10-K · filed 2023-02-10 | ||||
| 2021-09-30 | $3.66 10-Q · filed 2022-10-25 | $7.44 10-Q · filed 2022-10-25 | |||
| 2021-06-30 | $5.32 10-Q · filed 2022-08-03 | $8.36 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | $9.28 10-Q · filed 2022-05-06 | ||||
| 2020-12-31 | $12.95 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $12.99 10-Q · filed 2021-11-09 | $11.30 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $10.36 10-Q · filed 2021-08-06 | $10.16 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $10.11 10-Q · filed 2021-05-11 | ||||
| 2019-12-31 | $3.46 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $3.42 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $3.42 10-Q · filed 2020-08-14 | $3.42 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |